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Duration of immune responses after Ebola virus vaccination
In The Lancet Infectious Diseases, Milagritos Tapia and 
colleagues1 address two important facets of Ebola 
virus immunity: longevity of vaccine-induced immune 
responses and correlates of immunity. Early attempts 
at Ebola virus vaccines on the basis of traditional 
methods, such as inactivated preparations and 
subunit vaccines, were not eﬀ ective in animal studies2 
(although later publications on these platforms are 
more promising3). Subsequent studies used a wide 
diversity of vaccine platforms that had not been used 
in approved human vaccines, such as non-pathogenic 
viral vectors engineered to express Ebola virus surface 
glycoprotein.4 
Several vaccine platforms now exist that are eﬀ ective 
against Ebola virus in non-human primates, such as 
the non-replicating chimpanzee adenovirus (ChAd3) 
platform expressing the Ebola virus glycoprotein, as 
reported by Tapia and colleagues.1 The ChAd3 vaccine 
was shown to be protective in non-human primate 
studies, but speciﬁ c antibody and T-cell levels fell 
by 10 months, at which time the animals were less 
protected against Ebola virus challenge than before 
10 months.5 However, a modiﬁ ed vaccinia Ankara 
(MVA) booster vaccine provided protection against 
Ebola virus challenge 10 months after vaccination.
The published scientiﬁ c literature suggests that 
diﬀ erent vaccine platforms might have diﬀ erent 
corr elates of immunity in Ebola virus infection.6 The 
absence of standardised assays and the inherent 
diﬃ  culty with T-cell assays has limited side-by-side 
comparison of antibody and T-cell measurement in 
the diﬀ erent Ebola virus vaccines in both human and 
animal studies. For adenovirus-based vaccines, both 
Ebola virus-speciﬁ c total antibody concentrations and 
polyfunctional T-cell responses (T cells that produce 
two or more of interferon γ, tumour necrosis factor 
α, and interleukin 2) are associated with protection 
in non-human primates, although exact correlation is 
still being analysed.5,7,8
The data presented by Tapia and colleagues1 
substantially extend these studies in human 
volunteers, including four dose responses of the 
primary ChAd3 vaccination, with or without an MVA 
boost, in a large cohort. High-titre antibody responses 
were rapidly induced in most volunteers, with a 
signiﬁ cant increase at the highest vaccine dose. These 
titres increased after MVA boost and persisted for 
more than 6 months. T-cell responses were long lived 
in individuals receiving only the ChAd3 vaccination, 
but both the percentage of volunteers developing 
T-cell responses and the magnitude of polyfunctional 
T cells greatly increased after the MVA boost. The 
data suggest that both vaccines were well tolerated. 
The concentrations of anti-Ebola virus glycoprotein 
antibodies and polyfunctional T-cell responses after 
the MVA boost reached values associated with 
protection with adenovirus-based vacc ines in non-
human primates. At this point, how well non-human 
primate immune correlates relate to human protection 
is unknown.
Future experiments that will be important to 
analyse correlates of immunity in Ebola virus 
vaccination will probably include analysis of both total 
anti-Ebola virus antibodies and functional antibody 
responses (such as neutralising antibody titres and 
other functional tests). Generally speaking, vaccines 
against one filovirus are not cross-protective against 
other filoviruses. Because six distinct filoviruses 
are pathogenic in human beings, research into use 
of proven vaccine platforms to cover additional 
filoviruses will be important. 
Further studies might focus on immune responses 
and adverse events after vaccination in diﬀ erent 
populations. Although direct comparison of ﬁ eld 
studies with clinical trials near research institutions 
is diﬃ  cult, establishment of relative responses will 
be important. Genetic analysis of patients infected 
with a Sudan Ebola virus suggests that certain HLA 
haplotypes predispose patients to survival or lethality.9 
Genetic factors might contribute to immune responses 
and adverse events after vaccination,10 including 
variability in presentation of glycoprotein peptides to 
T cells. A ﬁ nal point is that standardised antibody and 
T-cell measurements need to be developed for use in 
diﬀ erent vaccine studies so that immune responses 
can be directly compared between diﬀ erent studies 
and groups. Such work is underway by the Filovirus 
Animal Non-Clinical Group11 and other organisations 
and should be expanded to include a wide range of 
antibody and T-cell assays.
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 Tenofovir alafenamide for HIV: time to switch?
Tenofovir disoproxil fumarate is a prodrug for 
tenofovir and is used as part of combination anti-
retroviral therapy (ART) for the treatment of HIV. 
Since its US approval in 2001, tenofovir disoproxil 
fumarate has become one of the most commonly used 
components of ART regimens and is a recommended 
by HIV treatment guidelines worldwide.1–3 Indeed, 
tenofovir disoproxil fumarate’s once-daily dosing 
and reassuring safety proﬁ le (combined with similar 
characteristics of other antiretroviral medications 
developed in the past decade) helped to revolutionise 
HIV treatment, allowing ART to be recommended 
earlier in the course of HIV disease, averting HIV-
related morbidity and onward transmission. 
Despite tenofovir disoproxil fumarate’s highly 
favourable characteristics, use has been associated 
with rare complications, particularly glomerular 
and tubular nephrotoxicity and decreased bone 
mineral density, which might be due to renal tubular 
dysfunction and associated phosphate wasting.4,5 
Recently, an alternative prodrug formulation of 
tenofovir, tenofovir alafenamide, has been developed. 
Tenofovir alafenamide achieves high concentrations 
of tenofovir intracellularly, particularly in blood 
mononuclear cells that are targets for HIV, but with 
concentrations in circulating plasma 90% lower than 
that after tenofovir disoproxil fumarate, thus reducing 
exposure to renal proximal tubular epithelial cells 
during tenofovir excretion. In two randomised trials 
of people with HIV starting their ﬁ rst ART regimen, a 
tenofovir-alafenamide-containing combination of 
elvitegravir, cobicistat, emtricitabine, and tenofovir 
alafenamide led to more than 90% of patients 
achieving virological suppression by week 48, with 
biomarkers suggesting signiﬁ cantly less renal and 
bone toxicity than with a similar regimen containing 
tenofovir disoproxil fumarate.6
If tenofovir alafenamide has a place in the initial 
treatment of HIV infection, then what about as an 
alternative for those already receiving tenofovir 
disoproxil fumarate? In The Lancet Infectious Diseases, 
Anthony Mills and colleagues7 report the results 
of a randomised, open-label, multicentre trial to 
assess whether eﬃ  cacy and toxicity was non-inferior 
to active-control when patients were switched 
from common regimens containing tenofovir 
disoproxil fumarate to the single tablet regimen of 
tenofovir alafenamide with elvitegravir, cobicistat, 
and emtricitabine. In the analysis of 959 patients 
randomly assigned to switch to a regimen containing 
tenofovir alafenamide and 477 to continue their 
tenofovir disoproxil fumarate regimen, no statistically 
signiﬁ cant diﬀ erence in virological suppression was 
evident at week 48 (932 patients [97%] vs 444 [93%], 
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